At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Colchicinedrug
Likely dose
Colchicine 1.2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-platelet Effects of Colchicine in Healthy Volunteers
In Brief
A Phase 4 clinical trial evaluating Colchicine for Healthy. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug administration, 2 hours after colchicine administration, and 24 hours after colchicine administration via the antecubital vein and evaluated for markers of platelet activity and inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionJan 2015
TodayJul 2026
First PostedMay 16, 2014
Enrollment StartMay 1, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.1 years ago
Interventions
Colchicinedrug
Colchicine 1.2 mg followed by 0.6 mg one hour later